Insights

Xcenda

Valuing CAR-T Therapies: Facing New Challenges, Fulfilling the Potential

Inverted color AmerisourceBergen icon
Xcenda
November 2018

Xcenda

Wearing Your Data: A Global Perspective

Inverted color AmerisourceBergen icon
Xcenda
November 2018

Xcenda

Catalonia: Understanding Market Access Within an Autonomous Region in Spain

Inverted color AmerisourceBergen icon
Xcenda
November 2018

Xcenda

Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments

Inverted color AmerisourceBergen icon
Xcenda
October 2018

Xcenda

Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?

Inverted color AmerisourceBergen icon
Xcenda
September 2018

Xcenda

Japan’s Ongoing Shift From a Traditional Reimbursement Assessment to a Novel Cost-Effectiveness Submission Requirement

Inverted color AmerisourceBergen icon
Xcenda
September 2018

Xcenda

Therapeutic Spotlight: Assessments of Emerging Therapies for Tardive Dyskinesia

Inverted color AmerisourceBergen icon
Xcenda
September 2018

Xcenda

Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division

Inverted color AmerisourceBergen icon
Xcenda
September 2018

Xcenda

HTA Quarterly | Fall 2018

Inverted color AmerisourceBergen icon
Xcenda
September 2018

Xcenda

HTA Quarterly | Late Summer 2018

Inverted color AmerisourceBergen icon
Xcenda
September 2018

Xcenda

Emerging Trends in PBM Restrictions on Commercial Copay Assistance

Corey Ford
Corey Ford, MHA
August 2018

AmerisourceBergen

How Policy Impacts Patient Support

Ana Stojanovska
August 2018

What role does the changing healthcare coverage landscape play in support program demand and design?

Xcenda

Portugal: A Glimpse into Europe's Future in an Era of Austerity and HTA Reform?

Inverted color AmerisourceBergen icon
Xcenda
July 2018

Xcenda

Connected Health: The Next Healthcare Frontier

Inverted color AmerisourceBergen icon
Xcenda
July 2018

AmerisourceBergen

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Ana Stojanovska
June 2018

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

AmerisourceBergen

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Ana Stojanovska
June 2018

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

Innomar Strategies

Top Trends in Health Policy in Canada: Insights from InnomarLive

Inverted color AmerisourceBergen icon
Innomar Strategies
June 2018

Xcenda

The European Medicines Agency to Find a New Home After Brexit

Inverted color AmerisourceBergen icon
Xcenda
June 2018

Xcenda

Are Emerging Value Frameworks a Path to Implementing Value-Based Pricing?

Inverted color AmerisourceBergen icon
Xcenda
June 2018

Xcenda

HTA Quarterly | Summer 2018

Inverted color AmerisourceBergen icon
Xcenda
June 2018

Xcenda

Applying Cost-Effectiveness Thresholds to the Real World: Implications on Access for Medicare Beneficiaries

Inverted color AmerisourceBergen icon
Xcenda
May 2018

Xcenda

Webinar: The Emergence of Copay Accumulator Programs

Corey Ford
Corey Ford, MHA
May 2018

Xcenda

State-Led: The Push for Transparency in Drug Pricing

Inverted color AmerisourceBergen icon
Xcenda
April 2018

AmerisourceBergen

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2018

Insights from managed care executives on the future of coverage and outcomes evaluation.

Xcenda

Seeing the Value and Transparency of Medicare Part B

Jennifer Snow, MPH
April 2018

Xcenda

HTA Quarterly Spring 2018

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Xcenda

Achieving Market Access Across the Globe for CGTs

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Xcenda

Payer Tactics to Manage Commercial Copay Assistance Gaining Traction

Corey Ford
Corey Ford, MHA
March 2018

Xcenda

Implementing Coverage With Evidence Development

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Xcenda

Recent Trends in Oncology Appraisal Decisions: NICE vs. SMC

Inverted color AmerisourceBergen icon
Xcenda
March 2018

Xcenda

Xcenda Examines the Impact of the Tax Cuts and Jobs Act on the Life Science Sector

Benjamin Parcher, PharmD, MS
February 2018

Xcenda

2018 Trends-Leaning Into the Chaos

Inverted color AmerisourceBergen icon
Xcenda
January 2018

Xcenda

Xcenda Collaborates with Family Reach on Critical Issue - Cancer-Related Financial Toxicity

Inverted color AmerisourceBergen icon
Xcenda
January 2018

AmerisourceBergen

What Do Payers Think About Digital Health Technologies

Inverted color AmerisourceBergen icon
AmerisourceBergen
September 2017

How are payers thinking about apps, wearables and other digital health technologies?

Xcenda

HTA Quarterly Late Summer 2017

Inverted color AmerisourceBergen icon
Xcenda
September 2017

Xcenda

Medical Nutritional Therapy: Achieving Reimbursement Across the Globe for Unique Non-drug Therapy Options

Inverted color AmerisourceBergen icon
Xcenda
September 2017

Xcenda

Brazil—The Largest Market in Latin America

Inverted color AmerisourceBergen icon
Xcenda
September 2017

Xcenda

Biologic Treatments for Severe Asthma—a Paradigm Shift From Targeted to More Personalized Medicine

Inverted color AmerisourceBergen icon
Xcenda
September 2017

Xcenda

HTA Quarterly | Summer 2017

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Xcenda

Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers

Jennifer Snow, MPH
August 2017

Xcenda

Hearing the Patient Voice: How 4 Countries are Utilizing Patient Input

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Xcenda

Understanding the Columbian Health Care Market

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Xcenda

HTAQ Summer 2017 Duchenne Muscular Dystrophy New and Revitalized Drugs Bring Hope to Patients

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Xcenda

Biosimilar Coding—Could There Be Billions in Hidden Savings?

Inverted color AmerisourceBergen icon
Xcenda
August 2017

Xcenda

Commercializing Cell and Gene Therapies

Inverted color AmerisourceBergen icon
Xcenda
June 2017

Xcenda

Payer Perceptions and Utilization of ICER Value Assessment Framework

Inverted color AmerisourceBergen icon
Xcenda
June 2017

Xcenda

FDAMA 114 and the 21st Century Cures Act

Inverted color AmerisourceBergen icon
Xcenda
May 2017

Xcenda

HTA Quarterly | Spring 2017

Inverted color AmerisourceBergen icon
Xcenda
May 2017

Xcenda

When the Outcome of an Appraisal Is Not NICE: An Overview of the Appeal Process

Inverted color AmerisourceBergen icon
Xcenda
May 2017

Xcenda

Navigating Coverage and Reimbursement for Immunotherapy in Oncology

Inverted color AmerisourceBergen icon
Xcenda
May 2017

Xcenda

Revisiting the Familiar: Time to Re-evaluate the GVD?

Inverted color AmerisourceBergen icon
Xcenda
May 2017

Xcenda

Xcenda Conducts Unique Research on Air Medical Services Costs

Inverted color AmerisourceBergen icon
Xcenda
March 2017

Xcenda

Multiple Myeloma: Rapidly Advancing Therapeutic Landscape

Inverted color AmerisourceBergen icon
Xcenda
January 2017

Xcenda

HTA Quarterly | Winter 2017

Inverted color AmerisourceBergen icon
Xcenda
January 2017

Xcenda

Indication-specific Pricing: What should manufacturers expect in key markets

Inverted color AmerisourceBergen icon
Xcenda
January 2017

Xcenda

HTA Quarterly | Fall 2016

Inverted color AmerisourceBergen icon
Xcenda
October 2016

Xcenda

Singapore: Key Insights Into One of the World’s Most Efficient Healthcare Systems

Inverted color AmerisourceBergen icon
Xcenda
October 2016

Xcenda

Psoriasis and Psoriatic Arthritis: Harnessing the Potential of Targeted Therapies

Inverted color AmerisourceBergen icon
Xcenda
October 2016

Xcenda

Rapid Access in the US, UK, and France

Inverted color AmerisourceBergen icon
Xcenda
October 2016

Xcenda

Analyzing the impact of Medicare Part D for Oncology Patients

Inverted color AmerisourceBergen icon
Xcenda
June 2016

Xcenda

Part B Drug Payment Change: Understanding the Implications for Pharma

Jennifer Snow, MPH
March 2016

Xcenda

Oncology in the Era of Value Frameworks: Perspectives Payers Oncologists Product Planning

Inverted color AmerisourceBergen icon
Xcenda
December 2015